Baird Maintains Outperform on Coherus BioSciences, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Colleen Kusy has maintained an Outperform rating on Coherus BioSciences (NASDAQ:CHRS) but has reduced the price target from $11 to $9.

January 23, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Baird analyst Colleen Kusy maintains an Outperform rating on Coherus BioSciences but lowers the price target from $11 to $9.
While the reduction in price target could suggest a tempered expectation for the stock's performance, the maintenance of an Outperform rating indicates that the analyst still sees positive potential in Coherus BioSciences. Investors may react to the lower price target with caution, but the reaffirmed positive rating could balance the sentiment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100